The planned phase 3 trial will be targeting patients with newly diagnosed NPM1 mutated AML and may pursue accelerated approval on the basis of measurable residual disease negative complete response as the primary endpoint. The gene discussed is NPM1; the disease is acute myeloid leukemia.